Phosphonic acid, [2-(1H-benzimidazol-1-yl)-1-hydroxyethylidene]bis-

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: Phosphonic acid, [2-(1H-benzimidazol-1-yl)-1-hydroxyethylidene]bis-
• 英文别名: [2-(benzimidazol-1-yl)-1-hydroxy-1-phosphonoethyl]phosphonic acid
• 化学式: C₉H₁₂N₂O₇P₂
• 分子量: 322.15
• InChiKey: YETRAIFXPZXEDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  153
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT
  申请人：Tsinghua University

  公开号：EP3348269A1

  公开（公告）日：2018-07-18

  Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjuvant.

  所公开的是作为高效疫苗佐剂的甲羟戊酸途径抑制剂及其用途。特别是，抑制剂是乙酰乙酰-CoA 转移酶抑制剂、HMG-CoA 合成酶抑制剂、HMG-CoA 还原酶抑制剂、甲羟戊酸激酶抑制剂、磷酸甲羟戊酸激酶抑制剂、甲羟戊酸-5-焦磷酸脱羧酶抑制剂、焦磷酸异戊烯酯异构酶抑制剂、焦磷酸法呢酯合成酶抑制剂、焦磷酸香叶酯合成酶抑制剂或香叶基香叶基转移酶 (I, II) 抑制剂。还公开了一种免疫原组合物，该组合物包含作为佐剂的甲羟戊酸途径抑制剂。
• Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant
  申请人：Tsinghua University

  公开号：US11382971B2

  公开（公告）日：2022-07-12

  Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjuvant.

  所公开的是作为高效疫苗佐剂的甲羟戊酸途径抑制剂及其用途。特别是，抑制剂是乙酰乙酰-CoA 转移酶抑制剂、HMG-CoA 合成酶抑制剂、HMG-CoA 还原酶抑制剂、甲羟戊酸激酶抑制剂、磷酸甲羟戊酸激酶抑制剂、甲羟戊酸-5-焦磷酸脱羧酶抑制剂、焦磷酸异戊烯酯异构酶抑制剂、焦磷酸法呢酯合成酶抑制剂、焦磷酸香叶酯合成酶抑制剂或香叶基香叶基转移酶 (I, II) 抑制剂。还公开了一种免疫原组合物，该组合物包含作为佐剂的甲羟戊酸途径抑制剂。
• MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT
  申请人：Tsinghua University

  公开号：US20190321465A1

  公开（公告）日：2019-10-24

  Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate to pathway as an adjuvant.
• MEVALONATE PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF
  申请人：TSINGHUA UNIVERSITY

  公开号：US20210008084A1

  公开（公告）日：2021-01-14

  Provided in the present invention is the use of a mevalonic acid pathway inhibitor in the preparation of a drug for treating and/or preventing tumours, inducing immunogenic death of tumour cells, inducing immune responses and activating T cells or DC cells to directly promote host immunity. Also provided in the present invention is a pharmaceutical composition comprising the mevalonic acid pathway inhibitor and an antitumour drug (for example, an immune checkpoint inhibitor and any drug that can lead to new antigen production) and a combination of the mevalonic acid pathway inhibitor and an antitumour drug (for example, an immune checkpoint inhibitor and any drug that can lead to new antigen production) and/or the radiotherapy.